Release Summary

Promedior, Inc. announced positive data from Stage 1 of an adaptive two-stage Phase 2 trial of PRM-151, a novel anti-fibrotic immunotherapy, in patients with myelofibrosis at ASH Annual Meeting.

Promedior, Inc.